Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/THOR-MEDICAL-21296150/news/Nordic-Nanovector-Asa-gibt-die-vollstandigen-Ergebnisse-der-klinischen-Phase-2-Studien-mit-Betaluti-43540173/?utm_source=whatsapp&utm_medium=social&utm_campaign=share